Recent Progress in the Therapeutic Role of Serelaxin in Vascular Dysfunction

Author(s): Ghulam Murtaza*, Adeel Siddiqui, Izhar Hussain.

Journal Name: Current Protein & Peptide Science

Volume 19 , Issue 11 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Cardiovascular (CV) diseases are caused by vascular dysfunction. The enhanced sensitivity to vasoconstrictors, reduced endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH) indicate CV dysfunction. In recent years, recombinant human relaxin, known as serelaxin, has emerged as a new vasoactive drug that is useful in acute heart failure. First part of this review article encompasses the role of endogenous relaxin in CV homeostasis. Subsequently, vascular effects of serelaxin and the underlying modes of action in comparison to other vasodilators are discussed. Finally, the usefulness of treatment with serelaxin in vascular dysfunction in different CV diseases, particularly due to oxidative stress, is explained.

Keywords: Recombinant human relaxin, acute heart failure, cardiovascular, endothelium-derived hyperpolarization, homeostasis, nitric oxide, prostacyclin, vasoconstrictors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 11
Year: 2018
Page: [1079 - 1087]
Pages: 9
DOI: 10.2174/1389203719666180709103020
Price: $58

Article Metrics

PDF: 18
HTML: 1